BioSpace News Archive

RedHill Biopharma Ltd., a specialty biopharmaceutical company primarily focused on the development and commercialization of clinical late-stage, proprietary drugs for the treatment of gastrointestinal diseases, announced that it has entered into a strategic collaboration with Cosmo Pharmaceuticals N.V.

We continue to show strong organic sales growth and improved margins in the third quarter”, says Mattias Perjos, President & CEO at Getinge.

Amgen and UCB announced that following a re-examination procedure, the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending Marketing Authorization for EVENITY® for the treatment of severe osteoporosis in postmenopausal women at high risk of fracture and with no history of myocardial infarction or stroke.

Arena Pharmaceuticals, Inc. will present new open-label extension data from the Phase 2 OASIS trial for its investigative drug candidate etrasimod, a next-generation, once-daily, oral, selective sphingosine 1-phosphate receptor modulator, in patients with moderately to severely active ulcerative colitis at the 25th Annual United European Gastroenterology Week.

ASLAN Pharmaceuticals, a clinical-stage oncology and immunology focused biopharma company, announced it has secured a US$3 million loan facility provided by the company’s chairman, members of the board, and several major investors.

Pooled analyses of the Phase 3 CAMP studies in molluscum contagiosum showed VP-102 achieved statistically significantly higher rate of complete lesion clearance and percentage of subjects with > 75% and > 90% lesion clearance rates over the course of therapy compared to vehicle

DEKRA Organizational Safety and Reliability, a global leader in safety at work, has announced a permanent and ongoing collaboration with Behavioral Safety Now for the 2020 Safety In Action Conference.

Bristol-Myers Squibb Company announced the extension of the expiration date of the offers to exchange notes issued by Celgene Corporation for up to $19,850,000,000 aggregate principal amount of new notes to be issued by Bristol-Myers Squibb Company and cash and the related consent solicitations being made by Bristol-Myers Squibb on behalf of Celgene to adopt certain proposed amendments to the indentures governing the Celgene Notes.

Centene Corporation and WellCare Health Plans, Inc. announced that the insurance departments of Arizona, Connecticut, Georgia, Ohio and Texas have now also approved Centene’s pending acquisition of WellCare, bringing the total number of states to approve the transaction to 24..

AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for RINVOQ™ (upadacitinib), a once-daily selective and reversible JAK inhibitor